Literature DB >> 1927259

Effectiveness of steroid treatment in myasthenia gravis: a retrospective study.

V Cosi1, A Citterio, M Lombardi, G Piccolo, A Romani, A Erbetta.   

Abstract

The records of 142 patients with generalized autoimmune myasthenia gravis who had been treated with steroids as the single immunosuppressive agent, collected at regular intervals, were employed for a retrospective evaluation. The effectiveness of treatment was assessed after 24 months; the data from the 6th and 12th months were also considered. After 24 months, 63.4% of the whole sample had improved (33.8% were in clinical or pharmacological remission); 13.4% were unchanged or had worsened and 22.3% had moved to a different immunosuppressive treatment. The rate of positive outcome was higher in patients over the age of 40 at disease onset.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1927259     DOI: 10.1111/j.1600-0404.1991.tb04899.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  10 in total

1.  Intercommunication between the neuroendocrine and immune systems: focus on myasthenia gravis.

Authors:  Jacqueline Mays; Cherié L Butts
Journal:  Neuroimmunomodulation       Date:  2011-09-22       Impact factor: 2.492

Review 2.  Perioperative management in myasthenia gravis: republication of a systematic review and a proposal by the guideline committee of the Japanese Association for Chest Surgery 2014.

Authors:  Yoshihisa Kadota; Hirotoshi Horio; Takeshi Mori; Noriyoshi Sawabata; Taichiro Goto; Shin-ichi Yamashita; Takeshi Nagayasu; Akinori Iwasaki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-01-22

3.  Satisfactory Response With Achieving Maintenance Low-Dose Prednisone in Generalized Myasthenia Gravis.

Authors:  Ahmad R Abuzinadah; Duaa Jabari; Omar Jawdat; Mamatha Pasnoor; Melanie Glenn; Laura Herbelin; April L McVey; Richard J Barohn; Mazen M Dimachkie
Journal:  J Clin Neuromuscul Dis       Date:  2018-12

4.  Minimal manifestation status and prednisone withdrawal in the MGTX trial.

Authors:  Ikjae Lee; Hui-Chien Kuo; Inmaculada B Aban; Gary R Cutter; Tarrant McPherson; Henry J Kaminski; Jon Sussman; Philipp Ströbel; Joel Oger; Gabriel Cea; Jeannine M Heckmann; Amelia Evoli; Wilfred Nix; Emma Ciafaloni; Giovanni Antonini; Rawiphan Witoonpanich; John O King; Said R Beydoun; Colin H Chalk; Alexandru C Barboi; Anthony A Amato; Aziz I Shaibani; Bashar Katirji; Bryan R F Lecky; Camilla Buckley; Angela Vincent; Elza Dias-Tosta; Hiroaki Yoshikawa; Marcia Waddington-Cruz; Michael T Pulley; Michael H Rivner; Anna Kostera-Pruszczyk; Robert M Pascuzzi; Carlayne E Jackson; Jan J G Verschuuren; Janice M Massey; John T Kissel; Lineu C Werneck; Michael Benatar; Richard J Barohn; Rup Tandan; Tahseen Mozaffar; Robin Conwit; Greg Minisman; Joshua R Sonett; Gil I Wolfe
Journal:  Neurology       Date:  2020-07-01       Impact factor: 9.910

Review 5.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

6.  Current and emerging treatments for the management of myasthenia gravis.

Authors:  Sivakumar Sathasivam
Journal:  Ther Clin Risk Manag       Date:  2011-07-22       Impact factor: 2.423

7.  Autoimmune neuromuscular disorders in childhood.

Authors:  Hugh J McMillan; Basil T Darras; Peter B Kang
Journal:  Curr Treat Options Neurol       Date:  2011-12       Impact factor: 3.598

8.  The Role of Osteopontin and Its Gene on Glucocorticoid Response in Myasthenia Gravis.

Authors:  Yanchen Xie; Hai-Feng Li; Liang Sun; Linda L Kusner; Shuhui Wang; Yunxiao Meng; Xu Zhang; Yu Hong; Xiang Gao; Yao Li; Henry J Kaminski
Journal:  Front Neurol       Date:  2017-05-31       Impact factor: 4.003

9.  Adverse Side Effects Associated with Corticosteroid Therapy: A Study in 39 Patients with Generalized Myasthenia Gravis.

Authors:  Stephen Johnson; Nakul Katyal; Naureen Narula; Raghav Govindarajan
Journal:  Med Sci Monit       Date:  2021-10-28

Review 10.  Corticosteroid Treatment-Resistance in Myasthenia Gravis.

Authors:  Henry J Kaminski; Jordan Denk
Journal:  Front Neurol       Date:  2022-04-25       Impact factor: 4.086

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.